ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

N,N,N',N'-Tetramethylazodicarboxamide → N-(3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl)-N-(2-(7-methyl-1-oxo-1H-isoquinolin-2-yl)ethyl)-2-nitrobenzenesulfonamide

HRID 1183100
ノート
印刷プレビュー

反応式

HRID 1183100 の反応式
CN(C)C(N=NC(N(C)C)=O)=O.C(P(CCCC)CCCC)CCC.[CH2:26]([N:28]1[C:34](=[O:35])[C:33]([CH3:37])([CH3:36])[C:32](=[O:38])[N:31]([CH3:39])[C:30]2[CH:40]=[C:41]([O:44][CH2:45][CH2:46][CH2:47][NH:48][S:49]([C:52]3[CH:57]=[CH:56][CH:55]=[CH:54][C:53]=3[N+:58]([O-:60])=[O:59])(=[O:51])=[O:50])[CH:42]=[CH:43][C:29]1=2)[CH3:27].O[CH2:62][CH2:63][N:64]1[CH:73]=[CH:72][C:71]2[C:66](=[CH:67][C:68]([CH3:74])=[CH:69][CH:70]=2)[C:65]1=[O:75]>ClCCl.O.C1COCC1>[CH2:26]([N:28]1[C:34](=[O:35])[C:33]([CH3:37])([CH3:36])[C:32](=[O:38])[N:31]([CH3:39])[C:30]2[CH:40]=[C:41]([O:44][CH2:45][CH2:46][CH2:47][N:48]([CH2:62][CH2:63][N:64]3[CH:73]=[CH:72][C:71]4[C:66](=[CH:67][C:68]([CH3:74])=[CH:69][CH:70]=4)[C:65]3=[O:75])[S:49]([C:52]3[CH:57]=[CH:56][CH:55]=[CH:54][C:53]=3[N+:58]([O-:60])=[O:59])(=[O:51])=[O:50])[CH:42]=[CH:43][C:29]1=2)[CH3:27]
参加物実験手順後処理出典と根拠反応ノート

参加物

8

反応物 4

HCID 4278N,N,N',N'-TetramethylazodicarboxamideHCID 13831TributylphosphineHCID 68672787N-(3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl)-2-nitrobenzenesulfonamideHCID 686736362-(2-hydroxyethyl)-7-methyl-2H-isoquinolin-1-one

生成物 1

HCID 68672764
N-(3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl)-N-(2-(7-methyl-1-oxo-1H-isoquinolin-2-yl)ethyl)-2-nitrobenzenesulfonamide
収率 65%

試薬・触媒・溶媒 3

HCID 962Water溶媒HCID 6344Dichloromethane溶媒HCID 8028Tetrahydrofuran溶媒

実験手順

N,N,N′,N′-Tetra methyl azodicarboxamide (TMAD) (118 mg) and tri-n-butyl phosphine (0.17 ml) were added to a THF solution (5 ml) of N-[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-2-nitrobenzenesulfonamide (231 mg) and 2-(2-hydroxyethyl)-7-methyl-2H-isoquinolin-1-one (93 mg), and stirred at room temperature overnight. Water was added to the reaction mixture, and extraction with dichloromethane was performed. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:methanol=20:1→10:1) The purified product was concentrated to dryness under reduced pressure to thereby obtain 205 mg (yield: 65%) of N-(3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl)-N-(2-(7-methyl-1-oxo-1H-isoquinolin-2-yl)ethyl)-2-nitrobenzenesulfonamide as a white amorphous solid.

後処理

  1. dry with materialThe organic layer was dried over anhydrous sodium sulfate
  2. concentrationconcentrated under reduced pressure
  3. customThe residue was purified by silica gel column chromatography (ethyl acetate:methanol=20:1→10:1) The purified product
  4. concentrationwas concentrated to dryness under reduced pressure

出典と根拠

ORDレコード
ord-2c75c6c8484944f5a6a8f1be9141cd4d
出典データセット
uspto-grants-2014_03
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08664217B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート